https://www.selleckchem.com/pr....oducts/napabucasin.h
Clinicians need this information as patients will require repeated BoNT treatments and may be unnecessarily but cumulatively exposed to potential immunogens. To underscore the need for caution and further evidence, we review some of the issues surrounding BoNT/A-induced immunogenicity and antibody-induced treatment failures and argue that using highly purified toxins that do not negatively impact patient outcomes is a prudent clinical decision. Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The A
Like
Comment
Share
